+357 96 030922
info@marketpublishers.com

Global Peptide-Radionuclide Conjugates (PRCs) Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

https://marketpublishers.com/r/GE3BDD9448B7EN.html
Date: August 2026
Pages: 93
Price: US$ 3,480.00 (Single User License)
ID: GE3BDD9448B7EN

Abstracts

According to our (Global Info Research) latest study, the global Peptide-Radionuclide Conjugates (PRCs) market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.

Peptide-Radionuclide Conjugates (PRCs) are advanced therapeutic and diagnostic tools used in nuclear medicine that combine a peptide, which specifically binds to certain receptors on cancer cells, with a radionuclide, which emits radiation. The peptide component targets and binds to receptors that are overexpressed on the surface of tumor cells, such as somatostatin receptors in neuroendocrine tumors. The attached radionuclide then emits either beta or alpha particles, which deliver targeted radiation directly to the cancer cells, leading to their destruction. This combination allows for highly specific treatment of cancerous tissues while minimizing damage to surrounding healthy tissues, making PRCs valuable in both imaging (for diagnosis) and therapy (for treatment).

The market for Peptide-Radionuclide Conjugates (PRCs) is experiencing significant growth, driven by advances in targeted cancer therapies and diagnostics. The increasing prevalence of cancers that express specific receptors, such as neuroendocrine tumors, has led to a rising demand for PRCs. These conjugates offer precise targeting and localized radiation treatment, making them a valuable tool in oncology. Additionally, the approval and commercialization of PRCs like ^177Lu-DOTATATE (Lutathera) have spurred interest and investment in this niche market, contributing to its expansion.

Recent trends highlight substantial progress in both the development and application of

+357 96 030922
info@marketpublishers.com

PRCs. Ongoing research and clinical trials are focused on improving the efficacy, safety, and specificity of these therapies. Innovations include the development of new peptides with enhanced receptor binding properties and novel radionuclides that may offer better therapeutic outcomes or reduced side effects. This research is not only expanding the indications for existing PRCs but also paving the way for new therapeutic and diagnostic options, further driving market growth.

Despite the positive outlook, the PRC market faces several challenges. High costs associated with the development and manufacturing of PRCs, along with the complexity of their production, can limit market accessibility and adoption. Additionally, competition from other targeted therapies and advancements in immunotherapy may influence market dynamics. Nevertheless, the continuous innovation in PRC technologies and the increasing number of clinical indications are likely to sustain market growth, offering promising prospects for both existing and emerging products in the sector.

This report is a detailed and comprehensive analysis for global Peptide-Radionuclide Conjugates (PRCs) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Peptide-Radionuclide Conjugates (PRCs) market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032

Global Peptide-Radionuclide Conjugates (PRCs) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032

Global Peptide-Radionuclide Conjugates (PRCs) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032

Global Peptide-Radionuclide Conjugates (PRCs) market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit),

+357 96 030922
info@marketpublishers.com

2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Peptide-Radionuclide Conjugates (PRCs)

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Peptide-Radionuclide Conjugates (PRCs) market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, RadioMedix, Curium Pharma, Telix Pharmaceutical, ITM Radiopharma, Grand Pharmaceutical, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation

Peptide-Radionuclide Conjugates (PRCs) market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

Diagnostic PRCs

Therapeutic PRCs

Market segment by Application

+357 96 030922
info@marketpublishers.com

Prostate Cancer

Neuroendocrine Tumors

Other

Major players covered

Novartis

RadioMedix

Curium Pharma

Telix Pharmaceutical

ITM Radiopharma

Grand Pharmaceutical

Market segment by region, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)

South America (Brazil, Argentina, Colombia, and Rest of South America)

Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:

Chapter 1, to describe Peptide-Radionuclide Conjugates (PRCs) product scope, market

+357 96 030922
info@marketpublishers.com

overview, market estimation caveats and base year.

Chapter 2, to profile the top manufacturers of Peptide-Radionuclide Conjugates (PRCs), with price, sales quantity, revenue, and global market share of Peptide-Radionuclide Conjugates (PRCs) from 2021 to 2026.

Chapter 3, the Peptide-Radionuclide Conjugates (PRCs) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Peptide-Radionuclide Conjugates (PRCs) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.

Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.

Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Peptide-Radionuclide Conjugates (PRCs) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.

Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.

Chapter 13, the key raw materials and key suppliers, and industry chain of Peptide-Radionuclide Conjugates (PRCs).

Chapter 14 and 15, to describe Peptide-Radionuclide Conjugates (PRCs) sales channel, distributors, customers, research findings and conclusion.

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

3 COMPETITIVE ENVIRONMENT: PEPTIDE-RADIONUCLIDE CONJUGATES (PRCS) BY MANUFACTURER

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Peptide-Radionuclide Conjugates (PRCs) Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Product link: https://marketpublishers.com/r/GE3BDD9448B7EN.html

Price: US$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GE3BDD9448B7EN.html